NABUMETONE IN ELDERLY PATIENTS WITH OSTEOARTHRITIS - ECONOMIC-BENEFITS VERSUS IBUPROFEN ALONE OR IBUPROFEN PLUS MISOPROSTOL

Nonsteroidal anti-inflammatory drugs (NSAIDs) vary in their potential to produce gastropathy. We compared the 3-month direct medical costs, including those associated with treating NSAID-induced adverse events, of nabumetone, ibuprofen, or ibuprofen plus misoprostol in 171 elderl y patients with osteoarthritis. Total direct medical costs per patient treated were $US183 for nabumetone, $US252 for ibuprofen, and $US270 for ibuprofen plus misoprostol. Differences resulted from higher costs associated with treatment of drug-related adverse events with ibuprof en, and higher drug acquisition prices with the combination regimen. S ensitivity analyses demonstrated that direct costs with nabumetone app roached those for the other 2 regimens if the price of nabumetone incr eased by 60%, the probability of lesion formation with nabumetone incr eased 4-fold, the probability of a lesion >0.5cm being symptomatic and needing treatment was 31%, or the price of misoprostol decreased by 5 0%. Although this study found more lesions because of mandated endosco pies than might be recognised or treated in clinical practice, the res ults suggest an economic benefit of nabumetone.